

Matthias Eiber

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8451985/publications.pdf>

Version: 2024-02-01

60
papers

6,639
citations

101543

36
h-index

123424

61
g-index

63
all docs

63
docs citations

63
times ranked

4967
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Evaluation of Hybrid ⁶⁸ Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. <i>Journal of Nuclear Medicine</i> , 2015, 56, 668-674. | 5.0 | 907 |
| 2 | ⁶⁸ Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1014-1024. | 6.4 | 589 |
| 3 | Assessment of ⁶⁸ Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer. <i>JAMA Oncology</i> , 2019, 5, 856. | 7.1 | 493 |
| 4 | Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT. <i>Journal of Nuclear Medicine</i> , 2018, 59, 469-478. | 5.0 | 372 |
| 5 | Detection Efficacy of ¹⁸ F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy. <i>Journal of Nuclear Medicine</i> , 2019, 60, 362-368. | 5.0 | 238 |
| 6 | Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 2117-2136. | 6.4 | 234 |
| 7 | ⁶⁸ Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning. <i>Journal of Nuclear Medicine</i> , 2018, 59, 230-237. | 5.0 | 226 |
| 8 | Value of ⁶⁸ Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1713-1719. | 5.0 | 213 |
| 9 | ^{99m} Tc-based Prostate-specific Membrane Antigen- ⁶⁷ Ga-radioguided Surgery in Recurrent Prostate Cancer. <i>European Urology</i> , 2019, 75, 659-666. | 1.9 | 195 |
| 10 | E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1626-1638. | 6.4 | 188 |
| 11 | Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy. <i>Journal of Nuclear Medicine</i> , 2017, 58, 76S-76S. | 5.0 | 163 |
| 12 | Value of a Dixon-based MR/PET attenuation correction sequence for the localization and evaluation of PET-positive lesions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1691-1701. | 6.4 | 161 |
| 13 | Matched-Pair Comparison of ⁶⁸ Ga-PSMA-11 PET/CT and ¹⁸ F-PSMA-1007 PET/CT: Frequency of Pitfalls and Detection Efficacy in Biochemical Recurrence After Radical Prostatectomy. <i>Journal of Nuclear Medicine</i> , 2020, 61, 51-57. | 5.0 | 161 |
| 14 | ¹⁷⁷ Lu-PSMA Radioligand Therapy for Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1196-1200. | 5.0 | 159 |
| 15 | The Impact of Somatostatin Receptor-Targeted PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis. <i>Journal of Nuclear Medicine</i> , 2017, 58, 756-761. | 5.0 | 158 |
| 16 | Preliminary Results for Characterization of Pelvic Lymph Nodes in Patients With Prostate Cancer by Diffusion-Weighted MR-Imaging. <i>Investigative Radiology</i> , 2010, 45, 15-23. | 6.2 | 143 |
| 17 | Diagnostic Accuracy of ⁶⁸ Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection. <i>JAMA Oncology</i> , 2021, 7, 1635. | 7.1 | 138 |
| 18 | Performance of Whole-Body Integrated ¹⁸ F-FDG PET/MR in Comparison to PET/CT for Evaluation of Malignant Bone Lesions. <i>Journal of Nuclear Medicine</i> , 2014, 55, 191-197. | 5.0 | 134 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Efficacy, Predictive Factors, and Prediction Nomograms for ⁶⁸ Ga-labeled Prostate-specific Membrane Antigen- ⁶⁸ Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1617-1623. | 1.9 | 129 |
| 20 | Impact of ⁶⁸ Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1153-1160. | 5.0 | 111 |
| 21 | ⁶⁸ Ga-PSMA PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment. <i>Prostate</i> , 2017, 77, 920-927. | 5.0 | 94 |
| 22 | Whole-body MRI including diffusion-weighted imaging (DWI) for patients with recurring prostate cancer: Technical feasibility and assessment of lesion conspicuity in DWI. <i>Journal of Magnetic Resonance Imaging</i> , 2011, 33, 1160-1170. | 2.3 | 89 |
| 23 | Potential Impact of ⁶⁸ Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1714-1721. | 3.4 | 83 |
| 24 | Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in Recurrent Prostate Cancer. <i>European Urology</i> , 2019, 76, 517-523. | 5.0 | 81 |
| 25 | Impact of ⁶⁸ Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy. <i>EJNMMI Research</i> , 2016, 6, 78. | 1.9 | 81 |
| 26 | Impact of ⁶⁸ Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1793-1799. | 2.5 | 78 |
| 27 | Comparison of ⁶⁸ Ga-PSMA-11 and ¹⁸ F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence. <i>Journal of Nuclear Medicine</i> , 2018, 59, 789-794. | 5.0 | 74 |
| 28 | Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 9-15. | 5.0 | 68 |
| 29 | ¹⁸ F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy. <i>Journal of Nuclear Medicine</i> , 2020, 61, 696-701. | 6.4 | 67 |
| 30 | Technologies for image-guided surgery for managing lymphatic metastases in prostate cancer. <i>Nature Reviews Urology</i> , 2019, 16, 159-171. | 5.0 | 67 |
| 31 | Targeted dual-energy single-source CT for characterisation of urinary calculi: experimental and clinical experience. <i>European Radiology</i> , 2012, 22, 251-258. | 3.8 | 62 |
| 32 | Systematic Comparison of the Performance of Integrated Whole-Body PET/MR Imaging to Conventional PET/CT for ¹⁸ F-FDG Brain Imaging in Patients Examined for Suspected Dementia. <i>Journal of Nuclear Medicine</i> , 2014, 55, 923-931. | 4.5 | 53 |
| 33 | Detection and classification of focal liver lesions in patients with colorectal cancer: Retrospective comparison of diffusion-weighted MR imaging and multi-slice CT. <i>European Journal of Radiology</i> , 2012, 81, 683-691. | 5.0 | 46 |
| 34 | Evaluation of T1 ρ as a potential MR biomarker for liver cirrhosis: Comparison of healthy control subjects and patients with liver cirrhosis. <i>European Journal of Radiology</i> , 2014, 83, 900-904. | 2.6 | 45 |
| 35 | PSMA ligands in prostate cancer – Probe optimization and theranostic applications. <i>Methods</i> , 2017, 130, 42-50. | 2.6 | 45 |
| 36 | | 3.8 | 43 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography. <i>European Urology</i> , 2022, 82, 156-160. | 1.9 | 43 |
| 38 | Non-invasive Differentiation of Kidney Stone Types using X-ray Dark-Field Radiography. <i>Scientific Reports</i> , 2015, 5, 9527. | 3.3 | 37 |
| 39 | Prospective phase 2 trial of PSMA-targeted molecular Radiotherapy with ¹⁷⁷ Lu-PSMA-617 for metastatic castration-resistant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1440-1446. | 5.0 | 37 |
| 40 | Establishing ¹⁷⁷ Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1786-1792. | 5.0 | 35 |
| 41 | Prostate-specific Membrane Antigen Positron Emission Tomography-detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation. <i>European Urology Focus</i> , 2021, 7, 309-316. | 3.1 | 34 |
| 42 | Simulation of a MR-PET protocol for staging of head-and-neck cancer including Dixon MR for attenuation correction. <i>European Journal of Radiology</i> , 2012, 81, 2658-2665. | 2.6 | 31 |
| 43 | Prostate-Specific Membrane Antigen-Guided Surgery. <i>Journal of Nuclear Medicine</i> , 2020, 61, 6-12. | 5.0 | 31 |
| 44 | False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 501-508. | 6.4 | 30 |
| 45 | Most of the Intended Management Changes After ⁶⁸ Ga-DOTATATE PET/CT Are Implemented. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1793-1796. | 5.0 | 24 |
| 46 | Detection Threshold and Reproducibility of ⁶⁸ Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1392-1397. | 5.0 | 21 |
| 47 | Can the Injected Dose Be Reduced in ⁶⁸ Ga-PSMA-11 PET/CT While Maintaining High Image Quality for Lesion Detection?. <i>Journal of Nuclear Medicine</i> , 2020, 61, 189-193. | 5.0 | 19 |
| 48 | Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study. <i>European Urology Oncology</i> , 2022, 5, 544-552. | 5.4 | 16 |
| 49 | Detection Efficacy of ¹⁸ F-PSMA-7.3 PET/CT and Impact on Management in Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Before Potential Salvage Treatment. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1719-1726. | 5.0 | 14 |
| 50 | Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [⁶⁸ Ga]PSMA-PET-guided metastasis-directed therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2328-2338. | 6.4 | 13 |
| 51 | Positron Emission tomography imaging in urological oncology: Current aspects and developments. <i>International Journal of Urology</i> , 2018, 25, 912-921. | 1.0 | 10 |
| 52 | Current Staging Procedures in Urinary Bladder Cancer. <i>Diagnostics</i> , 2013, 3, 315-324. | 2.6 | 9 |
| 53 | Gallium-68 HBED-CC-PSMA Positron Emission Tomography/Magnetic Resonance Imaging for Prostate Fusion Biopsy. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 245-247. | 1.9 | 8 |
| 54 | Entering the Era of Molecularly Targeted Precision Surgery in Recurrent Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2019, 60, 156-157. | 5.0 | 7 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Long-term effects on subscapularis integrity and function following arthroscopic shoulder stabilization with a low anteroinferior (5:30 oâ€™clock) portal. <i>Knee Surgery, Sports Traumatology, Arthroscopy</i> , 2016, 24, 422-429. | 4.2 | 6 |
| 56 | Practice changing for prostate cancer: a vision of the future. <i>Nature Reviews Urology</i> , 2019, 16, 71-72. | 3.8 | 6 |
| 57 | A New Type of Prostate Cancer Imaging: Will ⁶⁴ CuCl ₂ PET/CT Flourish or Vanish?. <i>Journal of Nuclear Medicine</i> , 2018, 59, 442-443. | 5.0 | 5 |
| 58 | Positive predictive value and correct detection rate of ¹⁸ F-rhPSMA-7 PET in biochemically recurrent prostate cancer validated by composite reference standard. <i>Journal of Nuclear Medicine</i> , 2021, 62, jnumed.120.255661. | 5.0 | 5 |
| 59 | Pre-test ⁶⁸ Ga-PSMA-ligand PET/CT positivity in early biochemical recurrent prostate cancer after radical prostatectomyâ€™ validation of a prediction model. <i>EJNMMI Research</i> , 2020, 10, 6. | 2.5 | 5 |
| 60 | Acceleration of PSMA-Targeted Theranostics to the Clinic: Can Common Sense Prevail?. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1186-1187. | 5.0 | 4 |